Remove 2013 Remove Conglomerates Remove Public Companies
article thumbnail

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever

The Motley Fool

The diversified healthcare conglomerate sells pharmaceuticals, medical devices, and various other products worldwide through its two units: Innovative Medicine and MedTech. The company is famous for having the highest credit rating available -- higher than the U.S. The stock offers a solid blend of income and growth.

article thumbnail

3 Simple Tricks That Every Investor Should Use (but Most Don't)

The Motley Fool

Study the management team and board of directors Public companies are obligated to apprise investors of who is on their management team, as well as provide the identities of prominent board members, directors, and major shareholders. So don't hesitate to buy competing businesses, as it often isn't contradictory in any way.

Investors 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Rule Breaker Investing Stock Stories, Vol. 9

The Motley Fool

This could be a very important year in investing, given what this tech company has gone on to do. Fast forward to 2013. I would retort, look, when sales are growing north of 40% annually, cash flow margins are 50-60%, and there's still a 7-10 year tailwind behind this company? David Gardner: The Facebook. I say, yes.

Investing 130
article thumbnail

How Good Is Your Market Cap Knowledge?

The Motley Fool

Adobe in 2013 with its Creative Cloud offering, began to shift the model. Is this a company you've studied? Yasser El-Shimy: It is not a company I have studied. In this city when you think of public companies based in Washington, DC, any standout performers come to mind for you? That's how Marriott started.

Taxes 130
article thumbnail

Transcript: William Cohan

The Big Picture

RITHOLTZ: Whereas all the other public companies had access to capital and managed to get into trouble. RITHOLTZ: So, you go from Lazard to Merrill to JPMorgan, tell us about those other experiences, how do they compare to Lazard which seems much more unique, being in a public company versus a partnership. RITHOLTZ: Sure.

Banks 103